by Sophiris Bio News Release

In: Posted Date, Publications, Published Date

No comments

Article published on November 24, 2011
Samuel Denmeade et al.

Background: PRX302 is a prostate specific antigen (PSA)–activated pore-forming protein toxin under development as a targeted approach for improving lowerurinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) without affecting sexual function.

Objective: To evaluate the safety andefficacy of PRX302inmenwithmoderate to severeBPH. Design, setting, and participants: Eligible subjects were refractory, intolerant, or unwilling to undergo medical therapies for BPH and had International Prostate Symptom Score (IPSS) 12, a quality of life (QoL) score 3, and prostate volumes between 30 and 80 g. Fifteen patients were enrolled in phase 1 studies, and 18 patients entered phase 2 studies. Interventions: Subjects received intraprostatic injection of PRX302 into the right and left transition zone via a transperineal approach in an office-based setting. Phase 1 subjects received increasing concentrations of PRX302 at a fixed volume; phase 2 subjects received increasing volumes per deposit at a fixed concentration.

Measurements: IPSS, QoL, prostate volume, maximum flow rate (Qmax), International Index of Erectile Function, serum PSA levels, pharmacokinetics, and adverse events were recorded at 30, 60, 90, 180, 270, and 360 d after treatment with PRX302. Results and limitations: Sixty percent of men in the phase 1 study and 64% of men in the phase 2 study treated with PRX302 had30% improvement compared to baseline in IPSS out to day 360. Patients also experienced improvement in QoL and reduction in prostate volume out to day 360. Patients receiving1 ml of PRX302 per deposit had the best response overall. PRX302 had no deleterious effect on erectile function. Adverse eventswere mild tomoderate and transient in nature. The major study limitation was the small sample size.

Conclusions: The promising safety profile and evidence of efficacy in the majority of treated subjects in these phase 1 and 2 studies supports further development of PRX302 as a minimally invasive, targeted treatment for BPH.

Download full publication »